<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The survival of patients with aggressive non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) is increasing, but the incidence of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> and late toxicity is poorly defined for those treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-hydroxydaunomycin/<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-Oncovin-<z:chebi fb="0" ids="8382">prednisone</z:chebi> (CHOP)-like chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>From February 1984 to January 1998, 2837 patients with aggressive NHL received the control-arm chemotherapy adriamycin-<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-<z:chebi fb="0" ids="36373">vindesine</z:chebi>-<z:chebi fb="0" ids="3139">bleomycin</z:chebi>-<z:chebi fb="0" ids="8382">prednisone</z:chebi> (ACVBP) in 3 consecutive <z:chebi fb="98" ids="24433">Groupe</z:chebi> d'Etude des Lymphomes de l'Adulte (GELA) studies </plain></SENT>
<SENT sid="2" pm="."><plain>With a median follow-up time of 74 months, the 5-year overall and event-free survival rates were 60% and 52% </plain></SENT>
<SENT sid="3" pm="."><plain>Two hundred two occurrences of nonneoplastic late toxicity were reported, resulting in a 5.35% cumulative probability of incidence at 7 years </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty-one second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> developed, for which the 7-year cumulative incidence rate was 2.75%; 64 were <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, and 17 were <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In multivariate analysis, age was the only risk factor for the second development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Epidemiologic analysis allowed a comparison of this NHL group with the general population </plain></SENT>
<SENT sid="7" pm="."><plain>Considering <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, no excess of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> was observed </plain></SENT>
<SENT sid="8" pm="."><plain>In the male population, however, there was an excess of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (standardized incidence ratio [SIR], 2.45; P &lt;.001) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (SIR, 5.65; P =.006), and in the female population there was an excess of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (SIR, 19.9; P &lt;.001) </plain></SENT>
<SENT sid="9" pm="."><plain>With a long follow-up, the ACVBP regimen was highly effective for the treatment of aggressive NHL </plain></SENT>
<SENT sid="10" pm="."><plain>Increases occurred in <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> among men </plain></SENT>
</text></document>